	US 11,730,769 B2
	Compositions and methods for Williams Syndrome (WS) therapy
Guoping Feng, Cambridge, MA (US); Boaz Barak, Cambridge, MA (US); and Zhigang He, Boston, MA (US)
Assigned to Children's Medical Center Corporation, Boston, MA (US); and Massachusetts Institute of Technology, Cambridge, MA (US)
Appl. No. 16/955,958
Filed by MASSACHUSETTS INSTITUTE OF TECHNOLOGY, Cambridge, MA (US); and CHILDREN'S MEDICAL CENTER CORPORATION, Boston, MA (US)
PCT Filed Dec. 21, 2018, PCT No. PCT/US2018/067092 § 371(c)(1), (2) Date Jun. 19, 2020, PCT Pub. No. WO2019/126643, PCT Pub. Date Jun. 27, 2019.
Claims priority of provisional application 62/610,063, filed on Dec. 22, 2017.
Prior Publication US 2020/0316132 A1, Oct. 8, 2020
Int. Cl. A61K 35/30 (2015.01); A61K 31/14 (2006.01); A61K 31/40 (2006.01); A61K 31/4409 (2006.01); C07K 16/28 (2006.01); A61K 45/06 (2006.01)

CPC A61K 35/30 (2013.01) [A61K 31/14 (2013.01); A61K 31/40 (2013.01); A61K 31/4409 (2013.01); C07K 16/2803 (2013.01); A61K 45/06 (2013.01)]

8 Claims

1. A method for treating Williams Syndrome in a subject, the method comprising:

administering a potassium channel blocker, or a pharmaceutically acceptable salt thereof, to the subject in need of such therapy in an amount sufficient to treat Williams Syndrome in the subject.